Volpara Health Technologies Ltd (ASX: VHT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Volpara Health Technologies Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$194.60 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
254.83 million
Earnings per share
-0.037
Dividend per share
N/A
Year To Date Return
42.86%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Volpara Health Technologies Ltd (ASX: VHT)
Latest News
Opinions
School-leaver to retiree: ASX stocks I'd buy for each age bracket
Opinions
I'd invest $10,000 into these excellent ASX shares for the long-term
Cheap Shares
I'd start snapping up quality cheap ASX shares before stock prices start rising!
Healthcare Shares
Why is the Volpara share price rocketing 13% today?
Opinions
ASX wealth: How I'd aim to turn $50,000 into $500,000 for retirement
Growth Shares
2 ASX growth shares I'd buy over Nvidia
Growth Shares
2 ASX growth shares I rate as buys for their big potential
Growth Shares
3 ASX growth shares I'd buy with $1,500 right now
Small Cap Shares
Why I'd buy small-cap shares over ASX blue chips at every chance
How to invest
How I'd build a 'best ASX stocks to buy right now' list
Share Market News
3 ASX shares using AI to help supercharge profits
Cheap Shares
How I'm aiming to find under-the-radar cheap ASX shares right now
Frequently Asked Questions
-
No, the ASX healthcare share has not yet paid any dividends.
-
Volpara listed on 27 April 2016.
VHT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Volpara Health Technologies Ltd
Volpara Health Technologies Ltd (ASX: VHT) is a small but growing research, development, and manufacturing company that provides breast screening technology and risk analysis for patients and medical professionals.
Volpara’s artificial intelligence-powered software for early detection of breast cancer is used by more than 2,000 facilities and more than 5,600 mammography technologists, impacting nearly 15 million patients globally. Volpara is based in Wellington, New Zealand, and also has a US office in Seattle.
VHT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 27 Nov 2023 | $0.80 | $0.05 | 6.67% | 449,665 | $0.72 | $0.80 | $0.71 |
| 24 Nov 2023 | $0.75 | $0.02 | 2.74% | 129,691 | $0.73 | $0.75 | $0.72 |
| 23 Nov 2023 | $0.73 | $0.01 | 1.39% | 50,407 | $0.73 | $0.73 | $0.71 |
| 22 Nov 2023 | $0.72 | $0.01 | 1.40% | 271,044 | $0.72 | $0.75 | $0.71 |
| 21 Nov 2023 | $0.72 | $0.02 | 2.86% | 172,092 | $0.70 | $0.72 | $0.69 |
| 20 Nov 2023 | $0.70 | $-0.02 | -2.78% | 80,274 | $0.74 | $0.74 | $0.70 |
| 17 Nov 2023 | $0.72 | $-0.02 | -2.70% | 16,532 | $0.73 | $0.74 | $0.72 |
| 16 Nov 2023 | $0.74 | $0.03 | 4.23% | 177,958 | $0.72 | $0.75 | $0.71 |
| 15 Nov 2023 | $0.71 | $0.03 | 4.44% | 109,596 | $0.68 | $0.71 | $0.68 |
| 14 Nov 2023 | $0.68 | $-0.01 | -1.46% | 193,179 | $0.69 | $0.69 | $0.67 |
| 13 Nov 2023 | $0.69 | $0.00 | 0.00% | 75,725 | $0.70 | $0.70 | $0.68 |
| 10 Nov 2023 | $0.69 | $0.01 | 1.48% | 47,139 | $0.70 | $0.70 | $0.68 |
| 09 Nov 2023 | $0.68 | $-0.03 | -4.23% | 126,674 | $0.71 | $0.72 | $0.67 |
| 08 Nov 2023 | $0.71 | $-0.02 | -2.76% | 42,837 | $0.73 | $0.73 | $0.71 |
| 07 Nov 2023 | $0.73 | $0.01 | 1.40% | 153,759 | $0.71 | $0.73 | $0.68 |
| 06 Nov 2023 | $0.72 | $-0.01 | -1.39% | 75,797 | $0.72 | $0.74 | $0.70 |
| 03 Nov 2023 | $0.72 | $-0.02 | -2.72% | 68,614 | $0.74 | $0.74 | $0.72 |
| 02 Nov 2023 | $0.74 | $-0.01 | -1.34% | 42,872 | $0.74 | $0.74 | $0.72 |
| 01 Nov 2023 | $0.75 | $0.01 | 1.36% | 208,106 | $0.72 | $0.76 | $0.71 |
| 31 Oct 2023 | $0.74 | $0.04 | 5.76% | 153,613 | $0.70 | $0.74 | $0.70 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 Aug 2023 | Mark Bouw | Issued | 450,000 | $585,000 |
Issue of options.
|
| 02 Jun 2023 | Teri Thomas | Sell | 3,577 | $2,546 |
On-market trade.
|
| 01 Jun 2023 | Teri Thomas | Buy | 75,280 | $57,213 |
Conversion of securities. As per announcement on 02-06-2023
|
| 01 Jun 2023 | Teri Thomas | Exercise | 75,280 | $57,213 |
Conversion of securities. 150,561 RSUs, As per announcement on 02-06-2023
|
| 16 Feb 2023 | Roger Allen | Exercise | 300,000 | $150,000 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Roger Allen | Non-Executive Director | Jun 2010 |
Roger was Volpara s first major investor, joined the Board
prior to FDA approval in June 2010, and was Chair from October 2015 to March 2019. Roger is a well-known entrepreneur, venture capitalist (VC), and social impact investor and philanthropist whose global career has spanned over 50 years. He helped pioneer the Australian technology industry through the Computer Power Group, one of the first Australian-founded tech companies to scale globally and subsequently IPO in 1987, turning over approx. $1B in today s currency. Following the companys acquisition in 1995, he cofounded Allen & Buckeridge Pty Ltd, one of the first early-stage VC firms. |
| Mr John Dimitrious Pavlidis | Non-Executive Director | Feb 2015 |
John Pavlidis joined the VHT board in February
2015 and has more than 30 years of experience as a senior healthcare executive, CEO, or company director in the areas of womens health, diagnostic imaging, image analysis and artificial intelligence, and cardiovascular therapies. |
| Mr Paul Reid | Non-Executive DirectorNon-Executive Chairman | Mar 2018 |
Paul joined the Board in March 2018 and brings extensive
commercial experience gained across a range of technology/Software as a Service businesses. He was the founding CEO and Chairman of Figured Limited, a fintech SaaS company that provides management accounting software to farmers in the United States, the United Kingdom , Australia, and New Zealand . Figured was the NZ Hi-Tech Startup Company of the Year in 2016 and has grown at an incredible pace, funded by private, corporate and venture capital (VC) investors. |
| Ms Karin Lindgren | Non-Executive Director | Jan 2020 |
Karin joined the Board in 2020. She brings over 35 years
experience in health information technology as a senior technology executive and law firm partner. As one of the earliest healthcare technology lawyers in the USA, Karin has an in-depth knowledge of data governance, data privacy, SaaS, and US healthcare, and has extensive professional networks across the IT landscape |
| Ms Ann Custin | Non-Executive Director | Sep 2021 |
network of industry contacts from an extensive
career in healthcare across Europe, the Americas, and Asia. Her most recent executive role was with Siemens Healthineers, where she served as both CFO and board director of Siemens Medical Solutions. Prior to this role, Ann served as Chief Operating and Financial Officer of Scientx and President & CEO of USA Draeger Medical Systems, Inc. |
| Ms Teri Thomas | Chief Executive OfficerManaging Director | Apr 2022 |
Teri joined the Board in October 2022. She has a
long history of executive management in healthcare IT ranging from strategy and operations to running global sales and marketing teams. This includes a 20-year career at Epic, a global leader in electronic health record (EHR) systems and other software solutions used by hospitals and healthcare organisations in the United States and internationally |
| Mr Mark Bouw | Non-Executive Director | Jan 2023 |
Mr Bouw is a experienced senior healthcare CEO .He is a visiting consultant at Stanford University Graduate Business School Seed Program in the United States and is a visiting mentor for Stanfords Ignite program.
|
| Mr Craig Hadfield | Chief Financial OfficerJoint Company Secretary | Mar 2017 |
-
|
| Mr Fred Struve | General CounselJoint Company Secretary | Oct 2022 |
-
|
| Craig Hadfield | Chief Financial OfficerJoint Company Secretary |
-
|
|
| Fred Struve | General CounselJoint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| No Top 20 | 27,534,688 | 10.84% |
| Patagorang Pty Ltd | 18,467,848 | 7.27% |
| Ralph Highnam And Kyc Trustees 106 Limited <Highnam Share A/C> | 16,213,561 | 6.38% |
| Citicorp Nominees Pty Limited | 11,830,450 | 4.66% |
| HSBC Custody Nominees (Australia) Limited | 8,187,911 | 3.22% |
| Custodial Services Limited <Beneficiaries Holding A/C> | 8,154,911 | 3.21% |
| Bnp Paribas Noms (Nz) Ltd <Drp> | 7,061,556 | 2.78% |
| Prof Sir Michael Brady | 6,619,075 | 2.61% |
| Mr Marcus Sarner | 5,980,404 | 2.35% |
| National Nominees Limited | 4,728,818 | 1.86% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient | 4,420,193 | 1.74% |
| Sir Martin Francis Wood | 3,004,655 | 1.18% |
| Lady Kathleen Audrey Wood | 3,004,654 | 1.18% |
| BNP Paribas Noms Pty Ltd <Drp> | 2,527,511 | 0.99% |
| Prof Martin Yaffe | 1,966,483 | 0.77% |
| Mr John Anthony Dell | 1,928,864 | 0.76% |
| BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Limited | 1,917,409 | 0.75% |
| Prof Nico Karssemeijer | 1,806,806 | 0.71% |
| Melbourne Securities Corporation Limited <Horizon 3 Biotech Fund A/C> | 1,519,964 | 0.60% |
| RX HOUSE TRUST PTY LTD | 880,758 | 0.35% |
